Gedeon Richter today announces the acquisition of the women’s health discovery portfolio of Celmatix Inc., (“Celmatix”) a US-based pioneering women's health biotech company dedicated to translating advances in female biology into novel therapeutics.
Gedeon Richter acquired Celmatix Therapeutics’ women’s health discovery portfolio, including programs spanning infertility, endometriosis, and ovarian aging. The portfolio includes an oral FSH receptor agonist, a JNK inhibitor, and early-stage AMH-targeting antibodies.
Celmatix Inc. and Celmatix Clinical Laboratories LLC describe their privacy practices for collecting, using, and disclosing information gathered through their websites and subdomains.
Celmatix Inc. maintains celmatix.com and its subdomains as a service to its user community under its Terms of Use. Celmatix also provides access to the free MyFertility Compass data analytics tool, which is governed by separate terms.